Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Jan;67(1):159–162. doi: 10.1038/bjc.1993.28

A pilot study of EVAP/ABV chemotherapy in 25 newly diagnosed children with Hodgkin's disease.

H Ekert 1, T Fok 1, L Dalla-Pozza 1, K Waters 1, P Smith 1, L White 1
PMCID: PMC1968223  PMID: 7678978

Abstract

Twenty five children with newly diagnosed Hodgkin's disease were clinically staged and treated with a chemotherapy protocol designed to reduce delayed toxicity. Four patients without macroscopic residual disease after biopsy received three cycles of hybrid EVAP/ABV. All remain in CR 31-46 months from diagnosis. One other developed fever and rash considered to be due to Ara-C and was treated with MOPP. Twenty patients had macroscopic residual disease after biopsy and were treated with two cycles of EVAP alone and reassessed with imaging and gallium scans. Twelve achieved CR, seven PR and one was not evaluable. Patients in CR were subsequently treated with 2-4 cycles of hybrid EVAP/ABV, while those in PR received 3-4 cycles. At a median follow up of 37 months the overall survival was 100%, relapse free 79% and treatment failure free 60%. Eight patients had mediastinal widening > 1/3 thoracic width. At the completion of the protocol five achieved CR, two PR and one was withdrawn from study at investigator preference. One patient has subsequently relapsed. Of the evaluable ten patients without a mediastinal presentation all achieved CR but three relapsed at 10, 13 and 18 months from diagnosis. Patients who achieved a PR only, relapsed or were withdrawn from study have been salvaged with MOPP or Ch1VPP chemotherapy.

Full text

PDF
159

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aubier F., Flamant F., Brauner R., Caillaud J. M., Chaussain J. M., Lemerle J. Male gonadal function after chemotherapy for solid tumors in childhood. J Clin Oncol. 1989 Mar;7(3):304–309. doi: 10.1200/JCO.1989.7.3.304. [DOI] [PubMed] [Google Scholar]
  2. Carbone P. P., Kaplan H. S., Musshoff K., Smithers D. W., Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971 Nov;31(11):1860–1861. [PubMed] [Google Scholar]
  3. Cavalli F. VP16-213 (etoposide). A critical review of its activity. Cancer Chemother Pharmacol. 1982;7(2-3):81–85. doi: 10.1007/BF00254526. [DOI] [PubMed] [Google Scholar]
  4. Corder M. P., Elliott T. E., Maguire L. C., Leimert J. T., Panther S. K., Lachenbruch P. A. Phase II study of cis-dischlorodiammineplatinum(II) in stage IVB Hodgkin's disease. Cancer Treat Rep. 1979 May;63(5):763–766. [PubMed] [Google Scholar]
  5. Dixon D. O., McLaughlin P., Hagemeister F. B., Freireich E. J., Fuller L. M., Cabanillas F. F., Gehan E. A. Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol. 1987 Oct;5(10):1670–1672. doi: 10.1200/JCO.1987.5.10.1670. [DOI] [PubMed] [Google Scholar]
  6. Ekert H., Waters K. D. Results of treatment of 18 children with Hodgkin disease with MOPP chemotherapy as the only treatment modality. Med Pediatr Oncol. 1983;11(5):322–326. doi: 10.1002/mpo.2950110505. [DOI] [PubMed] [Google Scholar]
  7. Ekert H., Waters K. D., Smith P. J., Toogood I., Mauger D. Treatment with MOPP or ChlVPP chemotherapy only for all stages of childhood Hodgkin's disease. J Clin Oncol. 1988 Dec;6(12):1845–1850. doi: 10.1200/JCO.1988.6.12.1845. [DOI] [PubMed] [Google Scholar]
  8. Longo D. L. The use of chemotherapy in the treatment of Hodgkin's disease. Semin Oncol. 1990 Dec;17(6):716–735. [PubMed] [Google Scholar]
  9. Meadows A. T., Obringer A. C., Marrero O., Oberlin O., Robison L., Fossati-Bellani F., Green D., Voûte P. A., Morris-Jones P., Greenberg M. Second malignant neoplasms following childhood Hodgkin's disease: treatment and splenectomy as risk factors. Med Pediatr Oncol. 1989;17(6):477–484. [PubMed] [Google Scholar]
  10. O'Dwyer P. J., Leyland-Jones B., Alonso M. T., Marsoni S., Wittes R. E. Etoposide (VP-16-213). Current status of an active anticancer drug. N Engl J Med. 1985 Mar 14;312(11):692–700. doi: 10.1056/NEJM198503143121106. [DOI] [PubMed] [Google Scholar]
  11. O'Reilly S. E., Klimo P., Connors J. M. The evolving role of etoposide in the management of lymphomas and Hodgkin's disease. Cancer. 1991 Jan 1;67(1 Suppl):271–280. doi: 10.1002/1097-0142(19910101)67:1+<271::aid-cncr2820671311>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  12. Robinson B., Kingston J., Nogueira Costa R., Malpas J. S., Barrett A., McElwain T. J. Chemotherapy and irradiation in childhood Hodgkin's disease. Arch Dis Child. 1984 Dec;59(12):1162–1167. doi: 10.1136/adc.59.12.1162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Rossof A. H., Coltman C. A., Jr, Jones S. E., Talley R. W. Phase II evaluation of cis-dichlorodiammineplatinum(II) in lymphomas: a Southwest Oncology Group Study. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1605–1608. [PubMed] [Google Scholar]
  14. Rybak M. E., McCarroll K., Kaplan R. J., Propert K. J., Budman D. R., Gottlieb A. J. Phase II trial of etoposide and cis-diaminodichloro-platinum in patients with refractory and relapsed Hodgkin's disease: Cancer and Leukemia Group B (CALGB) Study 8353. Med Pediatr Oncol. 1990;18(3):177–180. doi: 10.1002/mpo.2950180302. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES